Navigation Links
Verenium to Present at Upcoming Conferences
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced James Levine, President and Chief Executive Officer, will present at two upcoming conferences.

Mr. Levine will present at the upcoming Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011.  The presentation is expected to begin at 1:35 p.m. ET and will take place at the Waldorf=Astoria Hotel in New York City.  

Mr. Levine will also present at the upcoming Wedbush 2011 Clean Technology & Industrial Growth Conference on Thursday, September 15, 2011.  The presentation is expected to begin at 3:00 p.m. PT and will take place at The Westin in San Francisco, California.

Live webcasts of both presentations may be accessed by visiting the "Investors" section of Verenium's website at www.verenium.com.  A webcast replay will be available approximately one hour after the live webcasts end and will be accessible for 30 days following these conferences.  

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.

Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts:Kelly Lindenboom

Vice President, Corporate Communications

858-431-8580

kelly.lindenboom@verenium.com

Sarah Carmody

Manager, Corporate Communications

858-431-8581

sarah.carmody@verenium.com
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011
2. Verenium Announces Debt Repurchase
3. Verenium Announces Signing of Lease for New Office and Lab Space
4. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
5. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
6. Verenium to Present at Upcoming Conferences
7. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
8. Verenium to Present at MDB Capital Groups Bright Lights Conference
9. Verenium Announces Debt Repurchase
10. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
11. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... Today Aether announced that Aether and ... a Bill and Melinda Gates Foundation grant, to pursue a 3D ... Foundation, also known as the Gates Foundation, is said to be the largest transparently ...
(Date:8/17/2017)... ... 17, 2017 , ... Cynvenio Biosystems, Inc., a leader in ... of a new breast cancer monitoring study in partnership with Saint Luke’s Cancer ... for early detection of recurrent breast cancer using LiquidBiopsy and natural killer (NK) ...
(Date:8/16/2017)... ... August 16, 2017 , ... While art and science are often thought ... than one might think. A Mesh Is Also a Snare, a group exhibition ... Science Center’s Esther Klein Gallery (EKG) on August 17 and run through September 30. ...
(Date:8/16/2017)... , Aug. 16, 2017  Kingfisher Talent, the ... leadership development, and Virdis Group, global executive search specialists in ... that enables clients to leverage the expertise and reach of ... clients here in the Boston biotech ... of leadership talent throughout the US, Canada ...
Breaking Biology Technology:
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):